BIOCYTOGEN-B (02315) announced its first-quarter results for the three months ended March 31, 2026. The group recorded revenue of 433 million yuan, representing a 73.68% increase year-over-year. Net profit attributable to shareholders of the listed company was 104 million yuan, compared to a loss of 13.2458 million yuan in the same period last year. Basic earnings per share stood at 0.23 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments